Immuneering Taps Grant C. Bogle For Its Board As It Prepares For Commercialization

The former TESARO commercial chief oversaw ZEJULA's U.S. launch; Immuneering's lead cancer drug is still in clinical development.

Share
Immuneering Taps Grant C. Bogle For Its Board As It Prepares For Commercialization

Immuneering, which develops cancer medicines, appointed Grant C. Bogle to its board Monday while preparing commercially for atebimetinib, its lead drug candidate still in clinical development. The appointment, detailed in an SEC filing, brings the company a director who oversaw the U.S. launch of the ovarian-cancer drug ZEJULA.

Atebimetinib Before A Potential Launch

Immuneering co-founder and CEO Ben Zeskind said in the company's appointment announcement that Bogle would help guide its commercial readiness work as atebimetinib moves through clinical development. Immuneering has no medicines approved for sale.

The company's pancreatic-cancer results presented at ASCO in June put median overall survival at 17.3 months for atebimetinib combined with mGnP in first-line treatment.

Atebimetinib is a daily pill targeting MEK, a protein. In its annual report for the fiscal year ended December 31, 2025, Immuneering described plans to start a global late-stage trial in first-line pancreatic cancer, with enrollment expected to reach about 510 patients.

The drug belongs to a category Immuneering calls Deep Cyclic Inhibitors: small-molecule oral medicines designed to interrupt cancer-driving signals cyclically, rather than maintain continuous disruption. The company uses its own bioinformatics tools and three-dimensional tumor models to design drugs.

From ZEJULA To Oncology Restructuring

Bogle's pharmaceutical and biotechnology career spans more than four decades, covering oncology marketing, sales, strategy and market access. As TESARO's chief commercial officer, he established its U.S. commercial business and oversaw ZEJULA's launch.

He also ran Epizyme as president and CEO, leading a restructuring that cut costs and accelerated revenue growth before Ipsen bought the company in 2022. While on Nuvalent's board, Bogle worked with management on launch planning; GlaxoSmithKline bought Nuvalent in 2026.

Immuneering appointed Bogle as a Class III director. He will be paid under its arrangements for non-employee directors.

Immuneering's other clinical candidate, envometinib, is paused internally while the company seeks partners. Earlier discovery programs target additional cancer pathways.

Sources

More on Immuneering

All Immuneering (IMRX) coverage →